Trial Profile
Un-randomized, Open, Multiple-Dose Study to Evaluate the Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules (GLS4) /Ritonavir Tablets(RTV) in Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Morphothiadine (Primary) ; Ritonavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunshine Lake Pharma
- 21 Jul 2020 Status changed from recruiting to completed.
- 24 Aug 2018 New trial record